Clinical pharmacology of thalidomide

European Journal of Clinical Pharmacology

Volumn 57, Issue 5, 2001, Pages 365-376

  Eriksson, Tommy ^a   Björkman, Sven ^a   Höglund, Peter ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Pharmacokinetics; Stereoisomers; Thalidomide

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT; THALIDOMIDE;

BLOOD; CHEMISTRY; COMPUTER SIMULATION; HUMAN; REVIEW; STEREOISOMERISM;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; COMPUTER SIMULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; STEREOISOMERISM; THALIDOMIDE;

EID: 85047685836     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280100320     Document Type: Article

References (87)

1. Baidas SA, Winer EP, Fleming GF. Harris L. Pluda JM. Craw ford JG. Yamauehi H, et al (2000) Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 18:2710 2717
2. Bauer K.S. Shannon CD. Figg WD (199X) Inhibition of angiogencsis by thalidomide requires metabolic activation, which is species-dependent. Bioehem Pharmacol 55:1827-1834
3. Beckmann R (1962) Über das Verhalten von Thalidomide in Organismus. Arzneimittelforschung 12:1095-1098
4. Beckmann R. Kampf HH (1961) Zur quantitativen Bestimmung und /um qualitativen Nachweis von N-Phthalyl-glutaminsäureimid (Thalidomid). Arzneimittelforschung 11:185-190
5. Boughton B.I. Sheehan TMT. Wood J, O'Brien D. Butler M, Simpson A. Hale KA (1995) High-performance liquid Chromatographie assay of plasma lhalidomide: stabilization of specimens and determination of tentative therapeutic range for chronic graft-versus-host disease. Ann Clin Biochem 32:79 83
6. Braun AG. Weinreb SL (19X5) Teratogen metabolism: spontaneous decay products of thalidomide and thalidomide analogues are not bioactivated by liver microsomes. Teratog Carcinog Mutagen 5:149-158
7. Calabrese L. Fleischer AB (2000) Thalidomide: current and potential clinical applications. Am J M cd 108:487-495
8. Celgene Corporation (2000) Thalomide product monograph. Physicians' desk reference. Medical Economics Company. Montvale
9. Chao NJ. Parker PM, Niland JC. Wong RM, Dagis A, Long GD. Nademanee AP, el al (1996) Paradoxical effect of thalidomide prophylaxis on chronic graft-vs-host disease. Biol Blood Marrow Transplant 2:86 92
10. Chen T-L. Vogelsang GB, Petty BG. Brundrett RB, Noe DA. Santos GW. Colvin OM (1989) Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metah Dispos 17:402105
11. Clarke TE. Edom N. LarsonJ, Eindsey EJ (2001) Thalomid (lhalidomide) capsules. A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including oil-label prescribing. Drug Saf 24:87-117
12. Cole CH. Rogers PCJ. Pritchard S. Phillips G. Chan KW (1994) Thalidomide and the management of chronic graft-versus-hosl disease in children following bone marrow transplantation. Bone Marrow Transplant 14:937 942
13. Curran WJ. Hyg SM (1971) The thalidomide tragedy in Germany: the end of a historic medicoleeal trial. N Engl J Med 284:481 4X2
14. D'Amato RJ. Loughnan MS. Flynn E. Folkman J (1993) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082 4085
15. Ehninger G. Eger K, Stuhler A. Schuler U (1993) Thalidomide the need for a new clinical evaluation of an old drug. Bone Marrow Transplant 12[Suppl 3]:26-28
16. Ehrenpreis EE. Kane SV. Cohen EB. Cohen RD. Hanauer SB ( 19991 Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenlerology 117:1271-1277
17. Eisen T. Boshoff C. Mak I. Sapunar F. Vaughan MM. Pyle E, Johnston SRD. et al (2000) Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.' Br J Cancer 82:812 817
18. Eriksson T, Björkman S (1997) Handling of blood samples for determination of thalidomide. Clin Chem 43:1095-1096
19. Eriksson T. Björkman S. Fyge A, Eikberg H (1992) Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation. J Chromatogr B Biomed Sci Appl 582:21 I 216
20. Eriksson T. Björkman S. Roth B. Fyge A. Höglund P (1995) Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 7:44 52
21. Eriksson T.' Björkman S. Roth B. Fyge A. Höglund P (1998a) The enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality 10:223-228
22. Eriksson T. Björkman S. Roth B. Björk H. Höglund P (1998b) Hydroxylated metabolites of thalidomide: formation in vitro and in vivo in man. J Pharm Pharmacol 50:1-8
23. Eriksson T. Björkman S. Roth B, Höglund P (2000a) Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in humans. J Pharm Pharmacol 52:807-817
24. Eriksson T. Wallin R. Höglund P. Roth B. Qi Z. Östraat Ö. Björkman S (2000b) Eow bioavailability of rectally administered thalidomide. Am J Health Syst Pharm 57:1607-1610
25. Fabro S. Schumacher H. Smith RE. Stagg RBE, Williams RT (1965) The metabolism of thalidomide: some biological effects of thalidomide and its metabolites. Br J Pharmacol 25:352-362
26. Figg WD. Raje S. Bauer KS. Tompkins A. Venzon D. Bergan R, Chen A. el al (1999) Pharmacokinetics of thalidomide in an elderly prostate cancer population. J Pharm Sci 88:121-125
27. Fine HA. Figg WD. Jaeckle K, Wen PY. Kyrilsis AP. Eoeffler .IS. Levin VA. et al (2000) Phase II trial of the antiangiogenic agent lhalidomide in patients with recurrent high-grade sliomas. J Clin Oncol 18:708-715
28. Gordon GB. Spielberg SP, Blake DA. Balasubramanian V (1981l Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proe Natl Acad Sci USA 78:2545-2548
29. Green JN. Benson BN (1991) The spectrophotomelric determination of thalidomide in body fluids. J Pharm Pharmacol 13:117T-121T
30. Günzler V (1992) Thalidomide in human immunodeficiency virus (HIV) patients. Drug Saf 7:116-134
31. Hague D. Smith RL (1988) Enigmatic properties of (±)-thalidomide: an example of a stable racemic compound. Br J Clin Pharmucol 26:623
32. Hamauryudan V. Mat C, Saip S, Özyazgan Y, Siva A. Yurdakul S. Zwingenberger K, et al (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. Ann Intern Med 128:443 450
33. Harland CC, Steventon GB. Marsden JR (1995) Thalidomide-induced neuropathy and genetic differences in drug metabolism. Eur J Clin Pharmacol 49:1-6
34. Haslett P, Tramontana J. Burroughs M, Hempstead M. Kaplun G (1997a) Adverse reaction to thalidomide in patients infected with human immunodeficiency virus. Clin Infect Dis 24:12231227
35. Haslett P. Hempstead M, Scidman C, Diakun J. Vasquez D. Freedman VH, Kaplan G (1997b) The metabolic and immunologie effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 13:1047-1054
36. Heney D, Norfolk DR, Wheeldon J, Bailey CC. Lewis U, Barnard DL (1991 ) Thalidomide treatment for chronic graft-versus-host disease Br J Haematol 78:23-27
37. Huupponen R, Pyykkö K (1995) Stability of thalidomide in human plasma. Clin Chem41:1199
38. Höglund P. Eriksson T, Björkman S (1998) A double blind study of the sedative effects of the thalidomide enantiomers in humans. J Pharmacokinet Biopharm 26:363-383
39. Jacobson JM, Greenspan JS. Spritzler J, Ketter N. Fahey .IL, Jackson JB, Fox L, et al (1997) Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 21:1487-1493
40. Jacobson JM. Spritzler J, Fox L, Fahey JL, Jackson JB. Chernoff H. Wohl DA, et al (1999) Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. J Infect Dis 180:61-67
41. Kaplan G, Thomas S, Fierer DS. Mulligan K. Haslett PAJ, Fessel WJ, Smith LG. et al (2000) Thalidomide for the treatment of AlDS-associated wasting. AIDS Res Hum Retroviruses 16:1345 1355
42. Kelsev FO (1988) Thalidomide update: regulatory aspects. Teratology 38:221-226
43. Klausner JD. Makonkawkeyoon S, Akaresewi P. Nakata K. Kasinrerk W. Corral L, Dewar RL (1996) The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. Tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 11:247-257
44. Koch HP (1985) Thalidomide and congeners as anti-inflammatory agents. Prog Med Chem 22:165-242
45. Krenn M. Gamcsik MP. Vogelsang GB, Colvin OM, Leong KW (1992) Improvements in solubility and stability of thalidomide upon complexation with hydroxypropyl-cyclodextrin. J Pharm Sci 81:685-689
46. Kunz W (1956) N-Phthalyl glutaminsäure-imid. Arzneimittelforschung 6:42630
47. Lenz W (1988) A short history of thalidomide embryopathy. Teratology 38:203-215
48. Little RF. Wyvill KM. Pluda JM, Welles L, Marshall V, Figg WD. Newcomb FM. et al (2000) Activity of thalidomide in AIDSrelated Kaposi's sarcoma. J Clin Oncol 18:2593-2602
49. Lyon AW. Duran G. Raisys VA (1995) Determination of thalidomide by high performance liquid chromatography: methodological strategy for clinical trials. Clin Biochem 28:467-470
50. McBride WG (1961) Thalidomide and congenital abnormalities. Lancet 2:1358
51. Moreira AL. Sampaio EP, Zmuidzinas A, Frindt P. Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor a by enhancing mRNA degradation. J Exp Med 177:1675 1680
52. Muller GW (1997) Thalidomide: from tragedy to new drug discovery. Chemtech 27:21-25
53. Neuhert R, Ncubcrt D (1997) Peculiarities and possible mode of action of lhalidomide. In: Kavalock RJ. Daston GP (eds) Handbook of experimental pharmacology, vol. 124. Springer. Berlin Heidelberg New York, pp 41-119
54. Nightinggale SE (1998) From the food and drim administration. JAMA 280:872
55. Nishimura K. Hashimoto Y. hvasaki S (1994) S-lbrm of 7-metyl-N-(a)-phlhalimidoglutarimide. but not its R-form. enhances phorbol ester-induced tumour necrosis factor-2 production b\ human leukaemia cell HL-60: implication of optical resolution of thalidomidal effects. Them Pharm Bull (Tokyo) 42:1157-1159
56. Noormohamed FD. Youlc MS. Higgs CJ. Kook KA. Hawkins DA. Lant AF, Thomas SD (I999) Pharmacokinelics and hemodynamic effects of single oral dose of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. AIDS Res Hum Retroviruses 15:1047-1052
57. Ochonisky S. Verroust J, Bastuji-Garin S. Ciherardi R. Revuz J (1994) Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol 130:66-69
58. Östraat Ö. Riesbeck K. Qi Z. Eriksson T. Schatz H. Ekberg H (1996) Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory effect on lymphocyte function in vitro. Transpl Immunol 4:117-125
59. Parker PM. Chao N. Nademanee A. O'Donnell MR. Schmidt GM. Snyder DS. Stein AS ( 1995) Thalidomide as salvage therapy for chronic graft-versus host disease. Blood 86:3604-3609
60. Phillips PI-L Pluda .IM, Cheson BD (1996) Clinical trials using thalidomide. Oncology 10:1498-1501
61. Piscitelli SC, Figg WF. Hahn B. Kelly G. Thomas S. Walker R (1997) Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. Antimicrob Agents Chemolher 41:2797-2799
62. Rajkuniar SV. Witzig TE (2000) A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 26:351-362
63. Ramirez-Amador VA. Fsquivel-Pedraza L. Ponce-De-Eeon S. Reyes-Teran G. Gonzalea-Guevara M. Ponce-De-Eeon S. Sierra-Madero JG (2000) Thalidomide for human immunodeficiency virus-related oral ulcers: a double-blind placebocontrolled clinical trial. Clin Infect Dis 28:892-894
64. Reyés-Teran G, Sierra-Madero .IG. del Cerro VM. Arroyo-Figueroa H, Pasquetti A. Calva .1.1. Ruiz-Palacios GM (1996) Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 10:1501-1507
65. Sampaio EP. Sarno EN. Gaiilly R. Cohn ZA. Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor -j. production by stimulated human monocytes. .1 F.xp Med 173: 699-703
66. Sampaio EP. Kaplan G, Miranda A. Nery JAC. Miguel CP. Viana SM. Sarno EN (1993) The influence of thalidomide on the clinical and immunological manifestations of erythema nodosum leprosum. J Infect Dis 168:408 414
67. Schuler S. Ehninger U (1995) Thalidomide: rationale for renewed use in immunological disorders. Drug Sal 12:364-369
68. Schumacher H. Smith RL. Williams. RT (1965a) The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br J Pharmacol 25:324-337
69. Schumacher H. Smith RE. Williams RT ( 1965b) The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol 25:338-351
70. Schumacher H. Blake DA. Gillette JR (1968) Disposition of thalidomide in rabbits and rats. J Pharmacol Exp Ther 160:201-211
71. Schumacher HJ, Wilson JG. Terapane JF, Rosedale SL (1970) Thalidomide: disposition in rhesus monkey and studies of its hydrolysis in tissues of this and other species. J Pharmacol Exp Ther 173:265-269
72. Shannon EJ, Sandoval F. Krahenhuhl JL (1997) Hydrolysis of thalidornide abrogates its ability to enhance mononuclcar cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF'-z. Immunopharmacology 36:9-15
73. Shepard TH. Shiota K (1983) Bioactivation of thalidomide by monkey liver fraction in a rat limb culture system. Prou Clin Biol Res I 10:377-385
74. Sheskin J (1965) Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6:303-306
75. Singhal S. Mehta J. Desikan R. Avers D. Roberson P, Eddlemon P. Munchi N et al (1999) Amitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571
76. Teo SK. Coiburn WA. Thomas SD (1999) Single-dose oral pharmaeokinetics of three formulations of thalidomide in healtrn male volunteers. .1 Clin Pharmacol 39:1162-1168
77. Teo SK, Sabourin PJ, O'Brian K, Kook KA, Thomas SD (2000a) Metabolism of thalidomide in human microsomes. cloned human cytochrome P-450 isoen/ymes, and Hansen's disease-patients. J Biochem Mol Toxicol 14:140-147
78. Teo SK. Sehelller MR. Kook KA. Tracewell WG. Coiburn WA. Stirling DL Thomas SD (200()b) Effect of a high-fat meal on thalidomide pharmacokineties and the relative bioavailabilily of oral formulations in healthy men and women. Biopharm Drug Dispos 21:33-40
79. Trapnell CB. Donahue SR, Collins .IM. Flockhart DA. Thacker DA. Abernetln DR (1999) Thalidomide does not alter the pharmaeokinetics of ethinyl estradiol and norethindrone. C'lin Pharmaeol Ther 64:597-602
80. Tramontana JM. Utaipat U. Mollev A. Akaresewi P. Burroughs M. Makonkawkeyoon S. Johnson B. et al (1995) Thalidomide treatment reduces tumor necrosis factor a. production and enhances weiahl aain in patients with pulmonary tuberculosis. Mol Med 1:3X4-397
81. Tseng S. Pak G. Washenik K. Pomeranz MK. Shupack JL (1996) Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. .1 Am Acad Dermatol 35:969 979
82. Vasiliauskas EA. Kam LY. Abreu-Martin MT, Hassard PV, Papadakis KA. Yang H. Zeldis JB. et al (1999) An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 117: 1278-1287
83. Vogelsang GB. Farmer ER. Hess AD. Altamonte V, Beschorner WE. Jabs DA, Corio RL. et al (1992) Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326:1055-1058
84. Williams RT. Schumacher H. Fabro S, Smith RL (1965) The chemistry and metabolism of thalidomide. In: Robson. et al (eds) Symposium on embryopathic activity of drugs. J. and A. Churchill. London, pp S167-S18X2
85. Wnendt S. Finkuni M. Winter W. Ossig J, Raabe G. Zwingenberger K (1996) Enantioselective inhibition of TNF-7 release by thalidomide and thalidomide-analogues. Chirality 8:390 396
86. WulIT CH. Hojer H. Asboe-Hansen G. Brodthagen H (1985) Development of polyneuropathy durirm thalidomide therapy. Br J Dermatol 112:475-480
87. Zwingenberger K. Wnendt S (1996) Immunomodulation by thalidomide: systemic review of the literature and of unpublished observations. J Inflamm 46:177-211